PeproMene Bio, Inc. Announced Complete Response of The First Patient Treated in Its B-cell Non-Hodgkin Lymphoma (B-NHL) Phase 1 Clinical Trial of PMB-CT01 (BAFFR-CAR T Cells) at City of Hope
/PRNewswire/ -- PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies to treat cancers and immune disorders, today announced that...
United States Hazel Cheng Larryw Kwak Elizabeth Budde Department Of Hematology Hematopoietic Cell Transplantation Prnewswire Pepromene Bio Inc
Source: prnewswire.com